Stem Cell Q&A : Is there a possibility my body will reject mesenchymal stem cells (MSCs)?
Stem Cell Q&A is a reoccurring series of questions and answers from members and across the web.
Understanding Stem Cells: A Beginner’s Guide to Trusted Resources
New to stem cells? We’ve rounded up the best videos and articles to help you grasp the basics and explore real-world applications in regenerative medicine.
New Data from the ALLELE Trial: Tabelecleucel Shows Promising Outcomes in Posttransplant EBV+ PTLD
Updated findings from the ALLELE trial reveal that tabelecleucel, an off-the-shelf allogeneic EBV-specific T-cell therapy, continues to show clinical benefit in relapsed/refractory EBV+ PTLD. The treatment achieved a 51% overall response rate, with a median duration of response of 23 months and a favorable safety profile.
